Zobrazeno 1 - 10
of 1 880
pro vyhledávání: ''
Autor:
Paul Mitchell, G Rivalland, Hui Yu, Fred R. Hirsch, R. Mosher, L Churilov, K Asadi, Christopher J. Rivard, S Heynemann
Publikováno v:
Clinical Lung Cancer. 23:e90-e98
Background NaPi2b is a multi-transmembrane sodium-dependent phosphate transporter expressed at normal levels in several organs, including lung. High expression levels have been reported in various tumours including breast, thyroid, ovarian and non-sm
Autor:
Griselda Martrat, Jorge García-González, Guillermo Lopez-Vivanco, Santiago Viteri, J. Garde, Manuel Cobo, Miguel Sampayo, Rafael Rosell, Jose Miguel Sanchez, Niki Karachaliou, Ivanna Sullivan, Miguel Angel Molina-Vila, Andrea Malfettone, Margarita Majem
Publikováno v:
European Journal of Cancer. 159:174-181
Aim of the study The AZENT ( NCT02841579 ) study aimed to assess the efficacy and safety of first-line osimertinib in patients with epidermal growth factor receptor(EGFR)mutation–positive advanced non–small-cell lung cancer (NSCLC) and with a coe
Autor:
Tatiana Gamez, Carlos Vargas, Christian Rolfo, Pilar Archila, Luis Corrales, Oscar Arrieta, Claudio Martin, Jorge Otero, C. Sotelo, Hernán Carranza, Juan Esteban Garcia-Robledo, D. Mayorga, Luisa Ricaurte, Camila Ordóñez-Reyes, Lucia Zatarain Barron, L. Rojas, Rafael Rosell, Luis Mas, Alejandro Ruiz-Patiño, Maritza Bermudez, July Rodriguez, J. Ávila, Andrés F. Cardona, Gonzalo Recondo, Feliciano Barrón
Publikováno v:
Repositorio U. El Bosque
Universidad El Bosque
instacron:Universidad El Bosque
Universidad El Bosque
instacron:Universidad El Bosque
La activación de BIM es esencial para la apoptosis desencadenada por el inhibidor de la tirosina quinasa (TKI) del receptor del factor de crecimiento epidérmico (EGFR) en el cáncer de pulmón de células no pequeñas (CPCNP) con mutación de EGFR.
Autor:
Yuan Wu, Chester Kao, Tian Zhang, Neal Ready, Michael B. Datto, Eric Powers, Jeffrey M. Clarke, John H. Strickler, Michelle F. Green
Publikováno v:
Clinical Lung Cancer. 22:500-509
Introduction A high tumor mutational burden (TMB) (≥10 mut/Mb) has been associated with improved clinical benefit in non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICI) and is a tumor agnostic indication for pembroliz
Autor:
Steven Kao, Tessa A. Morris, Mark Voskoboynik, Benjamin Solomon, Luke McLean, Wasek Faisal, Ross Jennens, Sagun Parakh, Craig R. Lewis, Malinda Itchins, Adam R. Broad, Melvin Chin
Publikováno v:
JCO Precision Oncology. :561-568
PURPOSE Leptomeningeal disease (LMD) in epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma is associated with a poor prognosis and limited treatment options. Osimertinib is a potent third-generation EGFR tyrosine kinase inhibitor with
Autor:
Takaaki Tokito, Akihiro Bessho, Satoshi Igawa, Shinji Sasada, Nobuhiko Seki, Naoki Furuya, Yosuke Tanaka, Koichi Minato, Kaoru Kubota, Hideki Hayashi, Hirotoshi Iihara, Rintaro Noro, Takayuki Kaburagi, Tsuneo Shimokawa, Hiroaki Okamoto, Masanao Nakashima, Shingo Miyamoto, T. Hirose, Toshiyuki Harada
Publikováno v:
Lung Cancer. 161:49-54
Objectives Afatinib is an effective treatment for patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). However, the toxicity associated with this agent often leads to dose modifications. The aim
Autor:
Katsuhiko Shimizu, Yuji Nojima, Takeshi Kurosaki, Shinsuke Saisho, Mikio Oka, Toru Oga, Koji Kurose, Masao Nakata, Ai Maeda
Publikováno v:
Anticancer Research. 41:5469-5475
Background/aim We evaluated the efficacy of "the tumor immune microenvironment (TIME) classification" for predicting clinical response to immune checkpoint inhibitors (ICIs) in patients with non-small cell lung cancer (NSCLC). In addition, we aimed t
Autor:
Meena Thayu, A. Roshak, Jose Manuel Trigo, Jong Seok Lee, Keunchil Park, Santiago Viteri, Ramaswamy Govindan, Natasha B. Leighl, Ji-Youn Han, Paul Mitchell, Nahor Haddish-Berhane, James Chih-Hsin Yang, Chee Khoon Lee, Roland Elmar Knoblauch, Patricia Lorenzini, Byoung Chul Cho, Dawn Millington, Nicolas Girard, Alexander I. Spira, Tsung-Ying Yang, Rachel E. Sanborn, Eric B. Haura, J.C. Curtin, Matthew G Krebs, Pilar Garrido, Koichi Goto, Sang-We Kim, Dong Wan Kim, Karen L. Reckamp, Ki Hyeong Lee, Joshua Bauml, Joshua K. Sabari, Catherine A. Shu, John Xie
Publikováno v:
Park, K, Haura, E, Leighl, N B, Mitchell, P, Shu, C, Girard, N, Viteri, S, Han, J-Y, Kim, S-W, Lee, C K, Sabari, J, Spira, A, Yang, T-Y, Kim, D-W, Lee, K H, Sandborn, R, Trigo, J, Goto, K, Lee, J-S, Yang, J C-H, Govindan, R, Bauml, J M, Garrido, P, Krebs, M, Reckamp, K, Xie, J, Curtin, J, Haddish-Berhane, N, Roshak, A, Millington, D, Lorenzini, P, Thayu, M, Knoblauch, R & Cho, B C 2021, ' Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study ', Journal of Clinical Oncology . https://doi.org/10.1200/JCO.21.00662
PURPOSE Non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor ( EGFR) exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved tyrosine kinase inhibitors. Amivantamab, an EGFR-MET bispecific antibody with
Autor:
Takahiko Nakamura, Kenjiro Tsuruoka, Kiyoe Kanaoka, Yosuke Tamura, Yasuhito Fujisaka, Soichiro Ikeda, Tomoya Funamoto, Masafumi Imanishi, Isao Goto, Akihisa Imagawa, Hiroyuki Tsuji, Sho Mitsuya, Ninso Matsunaga
Publikováno v:
Anticancer Research. 41:5137-5145
BACKGROUND For epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), administration of EGFR tyrosine kinase inhibitors (TKIs) is mandatory to prolong survival. To date, a comparison of second- and third-generation EGFR-T
Autor:
Michelangelo Fiorentino, Filippo Gustavo Dall'Olio, Rita Golfieri, Laura Marcolin, Benedetta Fragomeno, Giada Grilli, Giulia Manferrari, Andrea Ardizzoni, Francesca Sperandi, Mario Terracciano, Nastassja Tober, Francesco Gelsomino, Nicole Conci, Francesca Fontana, Andrea De Giglio, Stefano Brocchi
Publikováno v:
Clinical Lung Cancer. 22:423-431
Background: Circulating tumor cells (CTCs) are a promising source of biological information in cancer. Data correlating PD-L1 expression in CTCs with patients’ response to immune checkpoint inhibitors (ICIs) in non–small-cell lung cancer (NSCLC)